Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
41.11
+0.20 (+0.49%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
30
31
Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
April 18, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
April 18, 2023
Shares of its takeover candidate nearly doubled on the news.
Via
Investor's Business Daily
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
April 18, 2023
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs
Via
Benzinga
This Favorable Sign Appears On GSK's Chart
April 14, 2023
Via
Benzinga
This House of Representative Just Sold Up To $100K In GSK Stock
April 05, 2023
Via
Benzinga
GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks
March 30, 2023
Via
Benzinga
Why Is Bellus Health (BLU) Stock Up 98% Today?
April 18, 2023
Bellus Health (BLU) stock is taking off on Tuesday after the company announced a $2 billion acquisition deal with GSK (GSK).
Via
InvestorPlace
GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition
April 18, 2023
Via
Benzinga
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
April 13, 2023
There's such a big need in preventing RSV that multiple companies should be big winners.
Via
The Motley Fool
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
April 11, 2023
The company bulks up its pipeline by regaining the rights to two of its clinical programs.
Via
The Motley Fool
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
April 11, 2023
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a...
Via
Benzinga
GSK Stock Skids On Judge's New Ruling As Zantac Trial Looms
March 24, 2023
A trial this summer will examine one Zantac user's cancer.
Via
Investor's Business Daily
This Is What Whales Are Betting On GSK
March 23, 2023
Via
Benzinga
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
April 11, 2023
- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will...
Via
Newsfile
Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging
April 10, 2023
While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Top Biotech Stocks to Buy in April
April 04, 2023
Right now you can pick up these stocks on the dip.
Via
The Motley Fool
Could This Move by Johnson & Johnson Equal Billions for Moderna?
April 02, 2023
An RSV vaccine could be a driver of blockbuster revenue.
Via
The Motley Fool
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis
March 31, 2023
A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),...
Via
Benzinga
Stage Set For Generics As Biden Admin Asks Supreme Court To Hear Skinny Labels Case Between GSK, Teva
March 31, 2023
Via
Benzinga
SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections
March 30, 2023
SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions
Via
Spotlight Growth
Why Is Scynexis (SCYX) Stock Up 69% Today?
March 30, 2023
Scynexis (SCYX) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme.
Via
InvestorPlace
Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug
March 30, 2023
Via
Benzinga
Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review
March 29, 2023
Via
Benzinga
J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out
March 29, 2023
The company says it's refocusing its portfolio to focus on transformational medicines.
Via
Investor's Business Daily
GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients
March 28, 2023
Via
Benzinga
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
March 27, 2023
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.
Via
MarketBeat
Recent Stock Purchases For March 2023
March 25, 2023
As readers may know by now, I make stock purchases every single month, no matter what is going on in the world. This month, I went heavier than I normally do, deploying over $3,000. Let's take a look.
Via
Talk Markets
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
March 21, 2023
Via
Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
March 20, 2023
Reuters
Via
Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
March 20, 2023
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.